EYPT (EyePoint) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


EYPT EyePoint Inc EYPT
34 GF Score
Price $13.66
GF Value $0.83
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

EyePoint's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

EYPT vs AKTS, OLMA, ZBIO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, EyePoint's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where EyePoint's Margin of Safety % (DCF Earnings Based) falls into.


EYPT
34GF Score
EyePoint Inc EYPT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $13.66 is trading 1545.8% above its estimated GF Value™ of $0.83. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.83 vs. price of $13.66 (1545.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.66
Price
$0.83
GF Value